Saturday 17 October 2026
Export FBLG’s income statement to Excel — free account
FibroBiologics Inc.
FBLG Healthcare Biotechnology
In the quarter to June 2026, EPS grew 72.5% and free cash flow grew 21.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.95
0.05
−5.00%
Follow FBLG
| Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|
Current Ratio |
0.27 | 0.37 | 1.00 | 1.12 | 3.61 |
Net Debt/EBITDA |
0.26 | 0.57 | 1.09 | 0.37 | 0.31 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 55.75% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 3.35 | 0.00 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.89 | 0.79 | 0.34 | 1.07 | 0.88 |
Capex/Depreciation |
— | 0.00 | (0.96) | (0.32) | (0.31) |
Interest Coverage |
(394.50) | (6.83) | (60.47) | (686.85) | (81.61) |
| 0.00% | 193.76% | 1,389.57% | (559.73%) | (419.44%) | |
| 0.00% | (193.54%) | (228.99%) | (78.97%) | (143.08%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | (824.53%) |
Return on Tangible Assets |
122.64% | 115.13% | (2,298.91%) | (479.84%) | (343.26%) |
Average Days of Receivables |
— | 0.00 | — | — | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
0.00 | (2.88) | (4.89) | (7.35) | (7.46) |
Cash per Share |
0.00 | 1.61 | 6.49 | 8.51 | 2.19 |
Shareholders Equity per Share |
0.00 | (2.83) | 0.89 | 1.66 | 2.76 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.00 | (2.83) | 0.89 | 1.66 | 2.76 |
Free Cash Flow |
(1.41) | (4.07) | (6.90) | (12.08) | (16.66) |
Working Capital |
(1.29) | (4.45) | 0.03 | 1.50 | 4.59 |
Capital Expenditures |
— | — | (0.49) | (0.18) | (0.26) |
Net Current Asset Value |
(1.29) | (6.19) | (1.35) | 0.52 | 2.89 |
| Other line items | |||||
Quick Ratio |
0.23 | 0.36 | 1.00 | 1.10 | 2.78 |
Depreciation/Fixed assets |
— | 0.00 | 0.65 | 0.70 | 0.99 |
Cash ROIC |
159.68% | 235.03% | (66.21%) | (46.68%) | (150.73%) |
Accounts Payable Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Revenue per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
0.00 | (2.88) | (4.53) | (7.24) | (7.34) |
Capex per Share |
— | 0.00 | (0.35) | (0.11) | (0.12) |
Average Payables |
— | 0.50 | 1.10 | 2.07 | 1.82 |
Average Assets |
— | 2.65 | 8.32 | 14.13 | 13.03 |
Average Common Equity |
— | (2.64) | (1.37) | 1.99 | 4.45 |
Capex to Sales |
— | — | 0.00 | 0.00 | 0.00 |
Columns are period end dates